IP Verse

Composition For The Treatment Of Prostate Cancer - EP2424503

The patent EP2424503 was granted to Ferring on Jul 5, 2017. The application was originally filed on Apr 30, 2010 under application number EP10726197A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2424503

FERRING
Application Number
EP10726197A
Filing Date
Apr 30, 2010
Status
Opposition Rejected
Jun 10, 2022
Publication Date
Jul 5, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZApr 5, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO03006049
INTERNATIONAL-SEARCH-REPORTWO2009101530
OPPOSITIONWO03006049

Non-Patent Literature (NPL) Citations (12) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- Anonymous, "TRADENAME® (degarelix for injection) for subcutaneous administration", FDA, (20081224), URL: www.accessdata.fda.gov/scripts/cder/daf, XP055481950
OPPOSITION- "Assessment report for Firmagon (doc ref:EMEA/CHMP/63576/2008)", European Medicines Agency (EMEA), (20090304), pages 1 - 67, XP055481967
OPPOSITION- CONN P.M., "Gonadotropin-releasing hormone and its analogs", Ann. Rev. Med., (19940000), vol. 45, pages 391 - 405, XP055481996
OPPOSITION- DOEHN CH. et al., "Drug evaluation: Degarelix - a potential new therapy for prostate cancer, (D3 of IPER of the EPO", IDrugs, (20060000), vol. 9, pages 565 - 572, XP009105353
OPPOSITION- "Open-Label, Randomized Parallel-Group Study View of NCT00728533 on 2009_02_19", Clinical trial, (20090219), XP055481905
OPPOSITION- Shunmugaperumal Tamilvanan, "5.2 Progress in design of biodegradable polymer-based microspheres for parenteral controlled delivery of therapeutic peptides/protein", Shunmugaperumal Tamilvanan, Shayne Cox, Pharmaceutical Manufacturing Handbook, pages 393 - 441, XP055481986
OPPOSITION- TAMMELA T. et al., "Dega relix - A phase II multicenter, randomized dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients", Europ. Urol. Suppl., (20050000), vol. 4, no. 3, page 228, XP055276667
OPPOSITION- SARTOR O., "Eligard0 6: A New Form of Treatment for Prostate Cancer", Eur. Urology Supplements, (20060000), vol. 5, no. 18, pages 905 - 910, XP005684027
OPPOSITION- JIANG G. et al., "GnRH antagonists: A new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6", Journal of Medical Chemistry, (20010000), vol. 44, no. 3, pages 453 - 467, XP009119476
OPPOSITION- RIVIER J. et al., "Gonadotropin-releasing hormone antagonists with Nw-triazolylornithine,- lysine, or -p-aminophenylalanine residues at positions 5 and 6", Journal of Medical Chemistry, (19920000), vol. 35, pages 4270 - 4278, XP002071776
OPPOSITION- BROQUA et al., "Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix", J. Pharamcol. Exp. Therapeut., (20020000), vol. 301, pages 95 - 102, XP055055233
OPPOSITION- SORBERA L.A. et al., "Degarelix Acetate", Drugs of the Future, (20060000), vol. 31, pages 755 - 766, XP002548773

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents